MedPath

WAKAYAMA MEDICAL UNIVERSITY

WAKAYAMA MEDICAL UNIVERSITY logo
๐Ÿ‡ฏ๐Ÿ‡ตJapan
Ownership
Private
Established
1945-01-01
Employees
-
Market Cap
-
Website
http://www.wakayama-med.ac.jp/intro/index.html

Isolation Procedure vs. Conventional Procedure During Distal Pancreatectosplenectomy for Pancreatic Cancer

Not Applicable
Recruiting
Conditions
Resectable Pancreatic Body/Tail Carcinoma
First Posted Date
2020-10-23
Last Posted Date
2020-10-23
Lead Sponsor
Wakayama Medical University
Target Recruit Count
100
Registration Number
NCT04600063
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Kobe University, Kobe, Hyogo, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Nara Medical University, Kashihara, Nara, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Kinki University, Sayama, Osaka, Japan

and more 7 locations

Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer

Phase 3
Conditions
Pancreatic Ductal Adenocarcinoma
Mesenteric Approach
Pancreaticoduodenectomy
First Posted Date
2017-10-23
Last Posted Date
2017-10-24
Lead Sponsor
Wakayama Medical University
Target Recruit Count
354
Registration Number
NCT03317886
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Kyusyu University, Fukuoka, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Kansai Medical University, Hirakata, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Hiroshima University, Hiroshima, Japan

and more 12 locations

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Phase 2
Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
First Posted Date
2017-08-17
Last Posted Date
2020-05-19
Lead Sponsor
Wakayama Medical University
Target Recruit Count
25
Registration Number
NCT03253068
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Wakayama Medical University, Wakayama, Japan

Study of NAC of GA Therapy for Patients With BRPC

Phase 2
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2016-10-06
Last Posted Date
2019-10-03
Lead Sponsor
Wakayama Medical University
Target Recruit Count
60
Registration Number
NCT02926183
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Hirosaki University, Hirosaki, Aomori, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Kobe University, Kobe, Hyogo, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

and more 15 locations

Combined Resection vs. Separated Resection After Mobilization of Splenic Vein During Distal Pancreatectomy

Phase 3
Conditions
Pancreatic Neoplasms
First Posted Date
2016-08-18
Last Posted Date
2016-08-18
Lead Sponsor
Wakayama Medical University
Target Recruit Count
304
Registration Number
NCT02871804
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Wakayama Medical University, Wakayama, Japan

The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.

Completed
Conditions
Pancreatic Cancer
First Posted Date
2016-05-19
Last Posted Date
2020-05-20
Lead Sponsor
Wakayama Medical University
Target Recruit Count
28
Registration Number
NCT02777463
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Wakayama Medical University, Wakayama, Wakayama Prefecture, Japan

Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.

Phase 1
Conditions
Pancreatic Cancer
Interventions
Drug: NAC-GEMABR
First Posted Date
2015-07-23
Last Posted Date
2016-05-12
Lead Sponsor
Wakayama Medical University
Target Recruit Count
10
Registration Number
NCT02506803
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Wakayama Medical University, Wakayama, Japan

Predictive Risk Factors for Pancreatic Fistula Grade C After Pancreaticoduodenectomy

Conditions
Disease of Pancreatic Head or Periampullary Lesions to Require Pancreaticoduodenectomy
First Posted Date
2014-12-23
Last Posted Date
2014-12-23
Lead Sponsor
Wakayama Medical University
Target Recruit Count
3000
Registration Number
NCT02322424
Locations
๐Ÿ‡จ๐Ÿ‡ณ

Chang Gun Memorial Hospital, Linkou, Taiwan

A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy

Phase 2
Completed
Conditions
Pancreatic Neoplasms
First Posted Date
2014-10-21
Last Posted Date
2016-07-21
Lead Sponsor
Wakayama Medical University
Target Recruit Count
120
Registration Number
NCT02270554
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Kansai Rosai Hospital, Amagasaki, Hyogo, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Kansai Medical University, Hirakata, Osaka, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Hiroshima University, Hiroshima, Hiroshima, Japan

and more 8 locations

Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study

Phase 1
Completed
Conditions
Patients With Borderline Resectable Pancreatic Cancer
Interventions
Drug: FIRINOX
First Posted Date
2014-05-28
Last Posted Date
2019-10-07
Lead Sponsor
Wakayama Medical University
Target Recruit Count
10
Registration Number
NCT02148549
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Nagoya University, Nagoya, Aichi, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Kobe University, Kobe, Hyogo, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Nara Prefectual Medical University, Kashihara, Nara, Japan

and more 6 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath